Featuring dual threaded design, the system is inserted between the proximal and middle phalanges, enabling opposing threads fixate on the phalangeal canal of the toe and compress the joint.
According to the company, the current standard of care for hammertoe correction is to treat patients with wire pins, which can break and dislodge.
Hammertoe system enables the implant to remain within the bone, helping in avoiding the follow up surgery to remove the pin.
The system, which is designed around one of 17 patents pending in the firm’s portfolio, represents the fifth 510(k) clearance for Centric Medical in the past one year.
Kyle Pearson of Rezin Orthopedics and Sports Medicine said: “Due to the advanced technology in this Hammertoe Correction System, the implant provides maintained correction through stability and compression at the PIPJ, and avoids the complications associated with K-wires.”
The company also produces Tarsa-Link stand-alone wedge fixation system, which is claimed to be the market’s first stand-alone osteotomy wedge with built-in fixation.
Centric plans to commercially introduce the system in the next month.
Centric Medical is a subsidiary of Life Spine, Inc., which is engaged in the development of surgical implants for the treatment of distal extremity pathology.
